Skip to content
AnalystLens

BridgeBio Pharma Annual Report, Year Ended Dec 31, 2025

Filing Date
Filed February 24, 2026
Period End
December 31, 2025
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Oct ’21Oct ’21
  3. Material agreement8-K · Sep ’23Sep ’23
  4. Material agreement8-K · Jul ’25Jul ’25

Summary

Summary of the 10-K filed February 24, 2026. Cited figures are marked; the original filing is the authoritative source.

BridgeBio Pharma, Inc. (BBIO) reports that it is a commercial-stage, multi-product biopharmaceutical company organized around a portfolio operating model.

Its largest product, Attruby (acoramidis) for ATTR-CM, generated $362.4 milliona in U.S. net product revenue in 2025, and total revenues, net were $502.1 million for 2025 compared with $221.9 million in 2024. The company still reported a net loss of $732.9 million for 2025 (versus $543.3 million in 2024), an accumulated deficit of $3.8 billion, and a working capital deficit position reflected in total stockholders' deficit of $2.08 billion at year-end. Cash, cash equivalents and marketable securities were $587.5 million as of December 31, 2025, and management states these resources plus Attruby revenue should fund operations for at least the next 12 months.

The filing highlights substantial debt and royalty obligations: total consolidated indebtedness of $1.9 billionb in convertible notes and deferred royalty obligations of $866.3 million. In January 2026 BridgeBio issued $632.5 million of 0.75% convertible senior notes due 2033. Pipeline catalysts include positive Phase 3 data for infigratinib in achondroplasia (PROPEL 3, February 2026), encaleret in ADH1 (CALIBRATE, October 2025) and BBP-418 in LGMD2I/R9 (FORTIFY interim analysis, October 2025), with NDA submissions planned for 2026 and an infigratinib MAA/NDA planned for the second half of 2026.

Beyonttra (acoramidis) is commercialized ex-U.S. through partners Bayer (Europe) and Alexion (Japan). Investors should weigh the commercial ramp of Attruby and the late-stage pipeline against continued losses, heavy operating expenses (selling, general and administrative expenses rose to $531.2 millionc), reliance on third-party manufacturers, and the cost and dilution implications of its debt and royalty financings. Exposure to U.S. drug pricing reforms, including proposed GLOBE and GUARD models and most-favored-nation initiatives, is also flagged as a risk to future revenue.

Key Highlights

  1. Net product revenue from Attruby reached $362.4 million in 2025, up from $2.9 million in 2024, following FDA approval in November 2024.
  2. Total revenues, net were $502.1 million in 2025 versus $221.9 million in 2024, with license and services revenue of $128.3 million and royalty revenue of $11.4 million.
  3. Net loss widened to $732.9 million in 2025 from $543.3 million in 2024; accumulated deficit reached $3.8 billion.
  4. Cash, cash equivalents and marketable securities totaled $587.5 million at December 31, 2025, which management expects to fund operations for at least the next 12 months.
  5. Total consolidated indebtedness of $1.9 billion in convertible notes plus $866.3 million of deferred royalty obligations; $632.5 million of 0.75% convertible notes due 2033 were issued in January 2026.
  6. Late-stage pipeline: positive Phase 3 data for infigratinib (achondroplasia), encaleret (ADH1) and BBP-418 (LGMD2I/R9), with planned NDA submissions in 2026.
  7. Management identifies U.S. drug pricing initiatives, including GLOBE, GUARD and most-favored-nation proposals, as a material risk to future product revenues.

Follow one dollar

For each $1.00 of revenue in FY2025, BridgeBio Pharma lost $1.44.

  1. Revenue$502.1M100.0%
  2. Cost of revenue−$21.0M4.2%
  3. Gross profit$481.1M95.8%
  4. Operating costs−$1.00B200.1%
  5. Operating income−$523.4M104.2%
  6. Interest, other & tax−$201.5M40.1%
  7. Net income−$724.9M144.4%
Computed from 10-KFY2025filed February 24, 2026Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

FY2025 against FY2024

Line itemFY2025FY2024Change
Revenue$502.08M$221.90M+126.3%
Cost of Revenue$20.96M$3.88M+440.5%
Gross Profit$481.11M$218.02M+120.7%
R&D Expenses$451.95M$506.46M−10.8%
SG&A Expenses$531.23M$288.93M+83.9%
Operating Expenses$1.03B$814.88M+25.8%
Operating Income-$523.41M-$592.97M+11.7%
Net Income-$724.93M-$535.76M−35.3%
EPS (Basic)$-3.78$-2.88−31.2%
EPS (Diluted)$-3.78$-2.88−31.2%
Shares Outstanding (Basic)191.53M186.08M+2.9%
Shares Outstanding (Diluted)191.53M186.08M+2.9%

Frequently Asked Questions

  1. What drove the increase in BridgeBio's 2025 revenue?

    Total revenues, net rose by $280.2 million to $502.1 million. Net product revenue increased by $359.5 million to $362.4 million, primarily from U.S. sales of Attruby. Royalty revenue increased by $11.2 million to $11.4 million, mainly from Beyonttra sales in Europe and Japan. License and services revenue fell by $90.5 million to $128.3 million, because 2024 included upfront license fees recognized under the Bayer and Kyowa Kirin agreements.

  2. How much cash does BridgeBio have and how long will it last?

    As of December 31, 2025, cash, cash equivalents and marketable securities totaled $587.5 million. Management states that these resources, together with proceeds from Attruby product revenue, are expected to be sufficient to fund operations through at least the next 12 months from the filing date. The company also notes it may need additional funding sooner if plans change.

  3. What is the company's debt and royalty financing position?

    The company reported total consolidated indebtedness of $1.9 billion, including the 2027, 2029 and 2031 convertible notes, and deferred royalty obligations of $866.3 million tied to the Funding Agreement and the Royalty Purchase Agreement. In January 2026, it issued $632.5 million of 0.75% convertible senior notes due 2033. The filing notes that these arrangements include covenants and that failure to comply could give purchasers remedies against collateral.

  4. What are the key upcoming catalysts for the pipeline?

    Management plans to submit an NDA to the FDA and an MAA to the EMA for low-dose infigratinib in achondroplasia in the second half of 2026, following positive PROPEL 3 topline results in February 2026. It also plans to submit an NDA for encaleret in ADH1 and for BBP-418 in LGMD2I/R9 in the first half of 2026. A registrational Phase 3 study of encaleret in chronic hypoparathyroidism is planned to start in 2026.

  5. What regulatory and pricing risks could affect future revenue?

    The filing cites proposed CMS models, GLOBE for Medicare Part B and GUARD for Medicare Part D, which would impose international-benchmark-based rebates if finalized, as well as GENEROUS, a voluntary Medicaid MFN model. It also notes Executive Orders on most-favored-nation pricing and the threat of tariffs on pharmaceuticals. Management says these measures could significantly affect U.S. net product revenue and international pricing strategy.